Serum aldosterone as a predictor of heart rhythm disorders in acute myocardial infarction

Nerma Resić, Mirza Dilić, Azra Durak-Nalbantić, Alen Džubur, Enisa Hodžić, Nina Hadžibegić, Marina Vučijak-Grgurević, Edin Begić


Introduction: In addition to the fastest reperfusion procedure

of coronary arteries blood flow, identification of patients with
increased risk of early and late complications is of the utmost
importance in acute myocardial infarction (AMI).
Methods: We included total of 207 patients in the acute phase
of myocardial infarction, which were divided into two groups,
127 patients without clinical symptoms of heart failure (HF)
and 60 patients with HF symptoms. For all patients serum aldosterone
levels were determined 24 hours after acute MI.
Results: In the group of decompensated patients, changes in
aldosterone level did not show a statistically significant effect
on paroxysmal supraventricular tachycardia (PSVT) occurrence
(p > 0.05), while in the group of compensated patients there is
statistically significant effect on PSVT occurrence (p =0.004).
Changes in aldosterone level in the group of decompensated
(p=0,030) and compensated patients (p=0,024), showed statistically
significant influence on the ventricular tachycardia (VT)
occurrence. In the group of compensated patients, changes in
aldosterone level showed a statistically significant effect on ventricular
fibrillation (VF) occurrence (p = 0.024).
Conclusion: Plasma aldosterone level in patients with acute
myocardial infarction has a significant influence on the occurrence
of cardiac rhythm disorders irrespective of the existence of
cardiac decompensation.
Keywords: aldosterone, myocardial infarction, prediction.

Full Text:



Koid SS, Campbell DJ. Evolving concepts of the renin-angiotensin

system: Highlights from the pre-ISH 2012 satellite

meeting. Journal of the Renin-Angiotensin-Aldosterone System.


Udell JA, Morrow DA, Braunwald E, Swedberg K, Bode

C, Rifai N, et al. Inhibition of the renin-angiotensin system

reduces the rise in serum aldosterone in acute coronary

syndrome patients with preserved left ventricular function:

observations from the AVANT GARDE-TIMI 43 trial.

Clinical chemistry. 2013;59(6):959-967.

Beygui F, Vicaut E, Ecollan P, Machecourt J, Van Belle E,

Zannad F, Montalescot G. Rationale for an early aldosterone

blockade in acute myocardial infarction and design

of the ALBATROSS trial. American heart journal.


Chai W, Danser AJ. Why are mineralocorticoid receptor antagonists

cardioprotective? Naunyn-Schmiedeberg’s archives

of pharmacology. 2006;374(3):153-62.

Opie LH, Gersh BJ. Drugs for the Heart E-Book. Elsevier

Health Sciences; 2011 Dec 1.

Funder JW. Aldosterone and mineralocorticoid receptors in

the cardiovascular system. Progress in cardiovascular diseases.


Catena C, Colussi G, Brosolo G, Iogna-Prat L, Sechi LA.

Aldosterone and aldosterone antagonists in cardiac disease:

what is known, what is new. Am J Cardiovasc Dis.

;2(1): 50-7.

Palmer BR. The measurement of plasma aldosteron

in patients post myocardial infarction. Eur Heart J.


Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO,

März W. Plasma aldosterone levels are associated with increased

cardiovascular mortality: the Ludwigshafen Risk

and Cardiovascular Health (LURIC) study. Eur Heart J.


Hansson GK, Hermansson A. The immune system in atherosclerosis.

Nat Immunol. 2011;12(3):204-12.

Bulluck H, Fröhlich GM, Mohdnazri S, Gamma RA, Davies

JR, Clesham GJ, et al. Mineralocorticoid Receptor Antagonist

Pretreatment to MINIMISE Reperfusion Injury After

ST‐Elevation Myocardial Infarction (The MINIMISE

STEMI Trial): Rationale and Study Design. Clin Cardiol.


Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci

C, Bueno H, et al. 2017 ESC Guidelines for the management

of acute myocardial infarction in patients presenting

with ST-segment elevation: The Task Force for the management

of acute myocardial infarction in patients presenting

with ST-segment elevation of the European Society of Cardiology

(ESC). Eur Heart J. 2017;39(2):119-77.

Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The

renin-angiotensin-aldosterone system in vascular inflammation

and remodeling. Int J Inflammation. 2014;2014.

Guichard JL, Donald Clark III DA, Ahmed MI. Aldosterone

receptor antagonists: current perspectives and therapies. Vascular

health and risk management. 2013;9:321-331.

Catena C, Colussi G, Marzano L, Sechi LA. Aldosterone

and the heart: from basic research to clinical evidence. Horm

Metab Res. 2012;44(3):181-7.

Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau

R, et al. Rationale and design of the treatment of

preserved cardiac function heart failure with an aldosterone

antagonist trial: a randomized, controlled study of spironolactone

in patients with symptomatic heart failure and preserved

ejection fraction. Am Heart J. 2011;162(6):966-72.

Catena C, Colussi G, Nait F, Martinis F, Pezzutto F, Sechi

LA. Aldosterone and the Heart: Still an Unresolved Issue?

Front Endocrinol (Lausanne). 2014;5:168.

Laszlo R, Bentz K, Konior A, Eick C, Schreiner B, Kettering

K, et al. Effects of selective mineralocorticoid receptor antagonism

on atrial ion currents and early ionic tachycardia-induced

electrical remodelling in rabbits Naunyn Schmiedebergs

Arch Pharmacol. 2010;382(4):347-56.

Laszlo R, Bentz K, Schreieck J. Effects of aldosterone and

mineralocorticoid receptor antagonism on cardiac ion channels

in the view of upstream therapy of atrial fibrillation Gen

Physiol Biophys. 2011;30 (1):11-9.

Beygui F, Labbé JP, Cayla G, Ennezat PV, Motreff P, Roubille

F et al. Early mineralocorticoid receptor blockade in

primary percutaneous coronary intervention for ST-elevation

myocardial infarction is associated with a reduction

of life-threatening ventricular arrhythmia. Int J Cardiol.


Shah NC, Pringle SD, Donnan PT, Struthers AD. Spironolactone

has antiarrhythmic activity in ischaemic cardiac patients

without cardiac failure. J Hypertens. 2007;25(11):2345-51.


  • There are currently no refbacks.